Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis Infection
- 15 March 2003
- journal article
- Published by American Thoracic Society in American Journal of Respiratory and Critical Care Medicine
- Vol. 167 (6), 809-810
- https://doi.org/10.1164/rccm.2301002
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Safety of 2 Months of Rifampin and Pyrazinamide for Treatment of Latent TuberculosisAmerican Journal of Respiratory and Critical Care Medicine, 2003
- Pyrazinamide and Rifampin vs Isoniazid for the Treatment of Latent TuberculosisSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2003
- Hepatotoxicity from Rifampin Plus PyrazinamideAmerican Journal of Respiratory and Critical Care Medicine, 2001
- Update: Fatal and Severe Liver Injuries Associated With Rifampin and Pyrazinamide for Latent Tuberculosis Infection, and Revisions in American Thoracic Society/ CDC Recommendations—United States, 2001American Journal of Respiratory and Critical Care Medicine, 2001
- Acceptability of Short-Course Rifampin and Pyrazinamide Treatment of Latent Tuberculosis Infection Among Jail InmatesSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2001
- Targeted Tuberculin Testing and Treatment of Latent Tuberculosis InfectionAmerican Journal of Respiratory and Critical Care Medicine, 2000
- Rifampin and Pyrazinamide vs Isoniazid for Prevention of Tuberculosis in HIV-Infected PersonsAn International Randomized TrialJama-Journal Of The American Medical Association, 2000
- Hepatotoxicity Associated With Isoniazid Preventive TherapyJAMA, 1999
- Twice weekly tuberculosis preventive therapy in HIV infection in ZambiaAIDS, 1998
- Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infectionThe Lancet, 1998